Cargando…

Old and new treatment targets in axial spondyloarthritis

Two main treatment targets in axial spondyloarthritis (axSpA) could be currently defined: (1) reduction of inflammation resulting in control of signs and symptoms such as pain and stiffness and (2) prevention or retardation of structural damage progression in the spine resulting in preservation of f...

Descripción completa

Detalles Bibliográficos
Autores principales: Rios Rodriguez, Valeria, Poddubnyy, Denis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4632151/
https://www.ncbi.nlm.nih.gov/pubmed/26557376
http://dx.doi.org/10.1136/rmdopen-2015-000054
_version_ 1782398971112587264
author Rios Rodriguez, Valeria
Poddubnyy, Denis
author_facet Rios Rodriguez, Valeria
Poddubnyy, Denis
author_sort Rios Rodriguez, Valeria
collection PubMed
description Two main treatment targets in axial spondyloarthritis (axSpA) could be currently defined: (1) reduction of inflammation resulting in control of signs and symptoms such as pain and stiffness and (2) prevention or retardation of structural damage progression in the spine resulting in preservation of functional status and improvement in the long-term outcome. A good control of signs and symptoms could be successfully achieved nowadays in the majority of patients treated with non-steroidal anti-inflammatory drugs (NSAIDs—the first-line therapy in axSpA) and with tumour necrosis factor (TNF) α blockers (the second-line therapy, if NSAIDs fail). Several pipeline drugs including interleukin (IL) 17 and IL-23 antagonists might be helpful in the immediate future in achievement of this treatment target in case of inefficacy of NSAIDs and TNFα blockers. Retardation of radiographical spinal progression in axSpA—disease modification—is currently a much more challenging task than a good symptom control. In this review, we discuss symptomatic and possible disease-modifying properties of current and forthcoming treatment options for axSpA.
format Online
Article
Text
id pubmed-4632151
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-46321512015-11-09 Old and new treatment targets in axial spondyloarthritis Rios Rodriguez, Valeria Poddubnyy, Denis RMD Open Proceedings from OsteoRheumatology 2014 Two main treatment targets in axial spondyloarthritis (axSpA) could be currently defined: (1) reduction of inflammation resulting in control of signs and symptoms such as pain and stiffness and (2) prevention or retardation of structural damage progression in the spine resulting in preservation of functional status and improvement in the long-term outcome. A good control of signs and symptoms could be successfully achieved nowadays in the majority of patients treated with non-steroidal anti-inflammatory drugs (NSAIDs—the first-line therapy in axSpA) and with tumour necrosis factor (TNF) α blockers (the second-line therapy, if NSAIDs fail). Several pipeline drugs including interleukin (IL) 17 and IL-23 antagonists might be helpful in the immediate future in achievement of this treatment target in case of inefficacy of NSAIDs and TNFα blockers. Retardation of radiographical spinal progression in axSpA—disease modification—is currently a much more challenging task than a good symptom control. In this review, we discuss symptomatic and possible disease-modifying properties of current and forthcoming treatment options for axSpA. BMJ Publishing Group 2015-08-15 /pmc/articles/PMC4632151/ /pubmed/26557376 http://dx.doi.org/10.1136/rmdopen-2015-000054 Text en Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
spellingShingle Proceedings from OsteoRheumatology 2014
Rios Rodriguez, Valeria
Poddubnyy, Denis
Old and new treatment targets in axial spondyloarthritis
title Old and new treatment targets in axial spondyloarthritis
title_full Old and new treatment targets in axial spondyloarthritis
title_fullStr Old and new treatment targets in axial spondyloarthritis
title_full_unstemmed Old and new treatment targets in axial spondyloarthritis
title_short Old and new treatment targets in axial spondyloarthritis
title_sort old and new treatment targets in axial spondyloarthritis
topic Proceedings from OsteoRheumatology 2014
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4632151/
https://www.ncbi.nlm.nih.gov/pubmed/26557376
http://dx.doi.org/10.1136/rmdopen-2015-000054
work_keys_str_mv AT riosrodriguezvaleria oldandnewtreatmenttargetsinaxialspondyloarthritis
AT poddubnyydenis oldandnewtreatmenttargetsinaxialspondyloarthritis